Malaysia
Search
Sign In
Gastroenterology
Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
Results of the NordICC* trial from Europe, presented at the United European Gastroenterology Week (UEG 2022), have hinted at the benefit of a single screening colonoscopy in preventing colorectal cancer (CRC).
Vonoprazan may be as effective as pantoprazole in reducing the risk of ulcers or bleeding following endoscopic variceal ligation (EVL) in patients with portal hypertension, according to a small study from Egypt presented at the United European Gastroenterology Week (UEG 2022).
In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.
The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.
